Literature DB >> 29763380

Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer.

Antonino Bruno1, Barbara Bassani1, Davide Giuseppe D'Urso1, Ilvana Pitaku2, Elisa Cassinotti2, Giuseppe Pelosi3, Luigi Boni4, Lorenzo Dominioni2, Douglas M Noonan1,5, Lorenzo Mortara5, Adriana Albini1,6.   

Abstract

NK cells are effector lymphocytes involved in tumor immunosurveillance; however, in patients with solid malignancies, NK cells have compromised functions. We have previously reported that lung tumor-associated NK cells (TANKs; peripheral blood) and tumor-infiltrating NK cells (TINKs) show proangiogenic, decidual NK-like (dNK) phenotype. In this study, we functionally and molecularly investigated TINKs and TANKs from blood and tissue samples of patients with colorectal cancer (CRC), a neoplasm in which inflammation and angiogenesis have clinical relevance, and compared them to NK cells from controls and patients with nononcologic inflammatory bowel disease. CRC TINKs/TANKs showed decreased expression for the activatory marker NKG2D, impaired degranulation activity, a decidual-like NK polarization toward the CD56brightCD16dim/-CD9+CD49+ subset. TINKs and TANKs secreted cytokines with proangiogenic activities, and induce endothelial cell proliferation, migration, adhesion, and the formation of capillary-like structures in vitro. dNK cells release specific proangiogenic factors; among which, angiogenin and invasion-associated enzymes related to the MMP9-TIMP1/2 axis. Here, we describe, for the first time, to our knowledge, the expression of angiogenin, MMP2/9, and TIMP by TANKs in patients with CRC. This phenotype could be relevant to the invasive capabilities and proangiogenic functions of CRC-NK cells and become a novel biomarker. STAT3/STAT5 activation was observed in CRC-TANKs, and treatment with pimozide, a STAT5 inhibitor, reduced endothelial cell capability to form capillary-like networks, inhibiting VEGF and angiogenin production without affecting the levels of TIMP1, TIMP2, and MMP9, indicating that STAT5 is involved in cytokine modulation but not invasion-associated molecules. Combination of Stat5 or MMP inhibitors with immunotherapy could help repolarize CRC TINKs and TANKs to anti-tumor antimetastatic ones.-Bruno, A., Bassani, B., D'Urso, D. G., Pitaku, I., Cassinotti, E., Pelosi, G., Boni, L., Dominioni, L., Noonan, D. M., Mortara, L., Albini, A. Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer.

Entities:  

Keywords:  STAT signaling; STAT3; STAT5; VEGF; angiogenesis

Mesh:

Substances:

Year:  2018        PMID: 29763380     DOI: 10.1096/fj.201701103R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  39 in total

1.  Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis.

Authors:  Thomas Beadnell; Lucia Borriello; Jessica Christenson; Jaime Fornetti; Ian Guldner; Ann Hanna; Lenka Kyjacova; Kristina Marinak-Whately; Poliana Cristina de Melo Martins; Mirja Rotinen; Veronika Te Boekhorst; Thomas R Cox
Journal:  Clin Exp Metastasis       Date:  2019-01-23       Impact factor: 5.150

Review 2.  Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.

Authors:  Denisa Baci; Elona Cekani; Andrea Imperatori; Domenico Ribatti; Lorenzo Mortara
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 3.  (Dis)similarities between the Decidual and Tumor Microenvironment.

Authors:  Jelena Krstic; Alexander Deutsch; Julia Fuchs; Martin Gauster; Tina Gorsek Sparovec; Ursula Hiden; Julian Christopher Krappinger; Gerit Moser; Katrin Pansy; Marta Szmyra; Daniela Gold; Julia Feichtinger; Berthold Huppertz
Journal:  Biomedicines       Date:  2022-05-04

4.  In vivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation.

Authors:  Ane Orrantia; Enrique Vázquez-De Luis; Gabirel Astarloa-Pando; Iñigo Terrén; Ainhoa Amarilla-Irusta; Diego Polanco-Alonso; Carmen González; Alasne Uranga; Tomás Carrascosa; Juan J Mateos-Mazón; Juan C García-Ruiz; Sergio Callejas; Ana Quintas; Ana Dopazo; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  iScience       Date:  2022-09-28

5.  High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.

Authors:  Kongfei Li; Lieguang Chen; Hua Zhang; Lu Wang; Keya Sha; Xiaohong Du; Daiyang Li; Zhongzheng Zheng; Renzhi Pei; Ying Lu; Hongyan Tong
Journal:  Aging (Albany NY)       Date:  2021-04-23       Impact factor: 5.682

6.  Renal cell tumors convert natural killer cells to a proangiogenic phenotype.

Authors:  Yue Guan; Christopher B Chambers; Taylor Tabatabai; Ha Hatley; Kristin R Delfino; Kathy Robinson; Shaheen R Alanee; Sophia Ran; Donald S Torry; Andrew Wilber
Journal:  Oncotarget       Date:  2020-06-30

7.  Salidroside inhibits migration and invasion of poorly differentiated thyroid cancer cells.

Authors:  Hongxia Shang; Shengnan Wang; Jinming Yao; Congcong Guo; Jianjun Dong; Lin Liao
Journal:  Thorac Cancer       Date:  2019-05-23       Impact factor: 3.500

8.  4-Hexylresorcinol and silk sericin increase the expression of vascular endothelial growth factor via different pathways.

Authors:  You-Young Jo; Dae-Won Kim; Je-Yong Choi; Seong-Gon Kim
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

Review 9.  Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

Authors:  Alia Ghoneum; Sameh Almousa; Bailey Warren; Ammar Yasser Abdulfattah; Junjun Shu; Hebatullah Abouelfadl; Daniela Gonzalez; Christopher Livingston; Neveen Said
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 15.707

Review 10.  Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.

Authors:  Antonino Bruno; Lorenzo Mortara; Denisa Baci; Douglas M Noonan; Adriana Albini
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.